Register for our free email digests:
Ryan Nelson
Executive Editor

Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ryan Nelson
Fragrance Creators Association Readies New Consumer Website To Cap ‘Year For The Public’
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.
FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?
Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.
US House Cosmetics Hearing: Preemption, FDA Ingredient Review Could Be Regulatory Reform Snags
Federal preemption of state and local requirements that differ from federal mandates came up repeatedly at the House Energy & Commerce Health Subcommittee’s 4 December cosmetics hearing. Meanwhile, both NGO and industry stakeholders generally support FDA review of cosmetic ingredients, but the details of such a framework likely will be contentious as work progresses.
House Energy & Commerce Chair Pallone Highlights Proposed Reform Bills Ahead Of Cosmetics Hearing
House Energy & Commerce Committee Chairman Frank Pallone underscores FDA’s lack of resources and insufficient “regulatory tools” in a memo to Health Subcommittee members going into a 4 December hearing on cosmetics safety issues. The committee’s last hearing on the subject was in 2012 when Pallone unveiled the first version of his Cosmetics Safety Enhancement Act.
FDA Warnings Target Companies US-Wide For Selling CBD Products That Violate Federal Law
CHART: The agency sent out 15 warning letters on 25 November, citing companies in 10 states for selling unapproved and misbranded CBD drug products in the guise of dietary supplements and cosmetics.
FDA Warns 15 CBD Product Marketers For Violations, Cautions Consumers: CBD May Harm You
The agency announces that it cannot conclude cannabidiol is GRAS, potentially heading off GRAS notifications and making NDI notifications a likelier future for CBD use in the supplement sector if any “lawful pathway” is to be found. In addition to a barrage of warning letters to marketers of CBD products, the FDA issued a stark warning to consumers about potential hazards.